TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Gossamer Bio ( (GOSS) ) is now available.
On September 24, 2025, Gossamer Bio, Inc. entered into an Option Agreement and Plan of Merger and Reorganization to potentially acquire Respira Therapeutics, Inc. through a merger with Prana Bio, Inc., Respira’s parent company. As part of the agreement, Gossamer Bio issued 2,500,000 shares of its common stock to Prana, with the option to issue additional shares and make milestone payments contingent on regulatory and sales achievements, impacting the company’s strategic positioning in the biopharmaceutical sector.
The most recent analyst rating on (GOSS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.
Spark’s Take on GOSS Stock
According to Spark, TipRanks’ AI Analyst, GOSS is a Underperform.
The overall stock score for Gossamer Bio is low, primarily due to significant financial challenges, including high leverage and consistent losses. While there is some improvement in revenue and cash flow, the company remains unprofitable. Technical analysis suggests market uncertainty, and valuation metrics show limited attractiveness due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on GOSS stock, click here.
More about Gossamer Bio
Gossamer Bio, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative therapeutics for the treatment of diseases with significant unmet needs.
Average Trading Volume: 3,770,218
Technical Sentiment Signal: Buy
Current Market Cap: $679.9M
Find detailed analytics on GOSS stock on TipRanks’ Stock Analysis page.